10 Defensive Stocks Billionaire Ken Fisher Is Betting On

2. Eli Lilly and Company (NYSE:LLY)

Beta Value: 0.50

Dividend Yield: 0.81%

Fisher Asset Management’s Q4 Stake: $4.04 billion

Number of Hedge Fund Holders: 115

Eli Lilly & Company (NYSE:LLY) is a notable global pharmaceutical firm that develops, manufactures, and sells a variety of pharmaceuticals. It was founded in 1876 and has since evolved to be one of the leading names in the global pharmaceutical industry.

On March 25, Bernstein analysts maintained an Outperform rating on Eli Lilly & Company (NYSE:LLY), with a $1,100 price target. The backing comes as competitor Novo Nordisk works on developing a medicine similar to Eli Lilly’s Retatrutide, a high-efficacy asset in the company’s pipeline. Despite the chance that Novo’s medicine might provide better weight loss results, Bernstein’s study supports Eli Lilly’s market lead with Retatrutide.

The company’s revenues increased by 45% in the fourth quarter of 2024 to $13.53 billion, owing to increased demand for Mounjaro and Zepbound. Meanwhile earnings per share increased dramatically by 102% to $4.88.